Literature DB >> 14616983

Short progression-free survival in myeloma patients receiving rituximab as maintenance therapy after autologous transplantation.

Pellegrino Musto, Angelo Michele Carella, Michele Mario Greco, Antonietta Falcone, Grazia Sanpaolo, Carlo Bodenizza, Nicola Cascavilla, Lorella Melillo, Angelo Michele Carella.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14616983     DOI： 10.1046/j.1365-2141.2003.04675.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  4 in total

1.  CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype.

Authors:  Teresa Paíno; Enrique M Ocio; Bruno Paiva; Laura San-Segundo; Mercedes Garayoa; Norma C Gutiérrez; M Eugenia Sarasquete; Atanasio Pandiella; Alberto Orfao; Jesús F San Miguel
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

2.  Apoptosis and complement-mediated lysis of myeloma cells by polyclonal rabbit antithymocyte globulin.

Authors:  Martin S Zand; Thuong Vo; Tina Pellegrin; Raymond Felgar; Jane L Liesveld; Jainulabdeen J Ifthikharuddin; Camille N Abboud; Ignacio Sanz; Jennifer Huggins
Journal:  Blood       Date:  2005-12-20       Impact factor: 22.113

3.  Circulating clonotypic B cells in multiple myeloma and monoclonal gammopathy of undetermined significance.

Authors:  Leandro S Thiago; Martin Perez-Andres; Ana Balanzategui; Maria E Sarasquete; Bruno Paiva; Maria Jara-Acevedo; Paloma Barcena; Maria Luz Sanchez; Julia Almeida; Marcos González; Jesus F San Miguel; Ramón Garcia-Sanz; Alberto Orfao
Journal:  Haematologica       Date:  2013-07-19       Impact factor: 9.941

4.  Antibody-based therapies in multiple myeloma.

Authors:  Yu-Tzu Tai; Kenneth C Anderson
Journal:  Bone Marrow Res       Date:  2011-03-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.